Evermine50 – Drug Eluting Stent (DES) – Meril Vascular Intervention

EVERMINE50 Breakthrough in DES Technology: Ultra-low strut thickness of 50μm for promoting early vascular healing Variable strut width and variable crown design to ensure adequate radial strength of 1.1bar* Hybrid cell stent design: Open cells in the middle of the stent for side-branch access and closed cell design on ends for optimal scaffolding and conformability Clinically established drug everolimus with biodegradable polymer for proven clinical safety & long term efficacy *Bench test data on file at Meril Life Sciences Visit our website to learn more about the product.